STI Stock Trade Intelligence
RAC

RACE ONCOLOGY LTD

Health Care · ASX:RAC
$1.69
▲ +7.30%
Market cap
$331M
Turnover
$208,063
Last price
$1.69
Day change
+7.30%
Announcements
16
Range, past year
Open 3.450 · Low 1.040 · Now 1.690 · High 4.900
Open RAC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

RAC momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
40/100
Wyckoff phase
Downtrend49d
Trend stage
Neutral
1 Day
+7.3%
1 Week
+15.4%
1 Month
+8.7%
1 Year
-48.5%
RSI
55
Avg daily range
5.9%

RACE ONCOLOGY LTD scores 40 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Downtrend, where it has been for 49 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently matching and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.88 — highly linear uptrend
  • RSI in healthy zone (55)
  • Near-term opportunity score 76
Points to watch
  • 60d drawdown -37.8%
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

RAC announcements

Recent price-sensitive releases.
  • 2026-10-22 Sept 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-12 HARNESS-1 First Cohort Cleared Progress Report
  • 2026-09-01 CPACS Trial Opens for RC220 Patient Enrolment in Korea Progress Report
  • 2026-08-25 Appendix 4E & Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-29 First HARNESS-1 Patient Safely Treated with RC220 Progress Report
  • 2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-03 Bellberry Ethics Approval Activates New HARNESS Trial Sites
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.